Adaptive Biotechnologies Corp (ADPT)

NASDAQ
Currency in USD
9.430
-0.080(-0.84%)
Real-time Data·
ADPT Scorecard
Full Analysis
2 analysts have revised their earnings upwards for the upcoming period
ADPT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.2909.790
52 wk Range
2.99010.280
Key Statistics
Edit
Prev. Close
9.51
Open
9.65
Day's Range
9.29-9.79
52 wk Range
2.99-10.28
Volume
394.11K
Average Vol. (3m)
2.43M
1-Year Change
171.71%
Book Value / Share
1.28
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ADPT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.143
Upside
+18.16%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week
Show more

Adaptive Biotechnologies Corp Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Adaptive Biotechnologies Corp Earnings Call Summary for Q1/2025

  • Adaptive Biotechnologies beats Q1 2025 EPS forecast with -$0.20 vs -$0.29 expected; revenue up 25% YoY to $52.4M
  • MRD revenue grew 34%; sequencing gross margin improved 17 percentage points to 62%; operating expenses decreased 9%
  • Stock surged 8.37% in aftermarket trading; company raised MRD revenue guidance to $180M-$190M for the year
  • Aims for adjusted EBITDA positivity in H2 2025; lowered operating expense guidance to $335M-$345M
  • COO highlights strong execution and confidence in meeting raised full-year guidance
Last Updated: 05/01/2025, 05:35 PM
Read Full Transcript

Compare ADPT to Peers and Sector

Metrics to compare
ADPT
Peers
Sector
Relationship
P/E Ratio
−10.1x−3.2x−0.5x
PEG Ratio
−0.280.060.00
Price / Book
7.5x2.0x2.6x
Price / LTM Sales
7.5x1.9x2.9x
Upside (Analyst Target)
18.0%47.9%53.0%
Fair Value Upside
Unlock5.3%8.9%Unlock

Analyst Ratings

7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 11.143
(+18.16% Upside)

Earnings

Latest Release
May 01, 2025
EPS / Forecast
-0.20 / -0.29
Revenue / Forecast
52.44M / 42.81M
EPS Revisions
Last 90 days

People Also Watch

2.4301
ASM
+1.25%
11.24
OUST
-2.01%
5.86
HTZ
-15.63%
24.760
SMMT
-1.98%
33.48
TGTX
-4.32%

FAQ

What Is the Adaptive Biotechnologies (ADPT) Stock Price Today?

The Adaptive Biotechnologies stock price today is 9.43

What Stock Exchange Does Adaptive Biotechnologies Trade On?

Adaptive Biotechnologies is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Adaptive Biotechnologies?

The stock symbol for Adaptive Biotechnologies is "ADPT."

What Is the Adaptive Biotechnologies Market Cap?

As of today, Adaptive Biotechnologies market cap is 1.44B.

What Is Adaptive Biotechnologies's Earnings Per Share (TTM)?

The Adaptive Biotechnologies EPS (TTM) is -0.96.

When Is the Next Adaptive Biotechnologies Earnings Date?

Adaptive Biotechnologies will release its next earnings report on Jul 30, 2025.

From a Technical Analysis Perspective, Is ADPT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.